| Year |
Citation |
Score |
| 2023 |
Delany-Moretlwe S, Flexner C, Bauermeister JA. Advancing use of long-acting and extended delivery HIV prevention and treatment regimens. Journal of the International Aids Society. e26126. PMID 37439079 DOI: 10.1002/jia2.26126 |
0.393 |
|
| 2022 |
Flexner C. The future of long-acting agents for preexposure prophylaxis. Current Opinion in Hiv and Aids. 17: 192-198. PMID 35762373 DOI: 10.1097/COH.0000000000000735 |
0.332 |
|
| 2022 |
Flexner CW, Kashuba A. Editorial: New drugs for HIV: quo vadis? Current Opinion in Hiv and Aids. 17: 1-3. PMID 34871186 DOI: 10.1097/COH.0000000000000710 |
0.42 |
|
| 2021 |
Chandiwana NC, Serenata CM, Owen A, Rannard S, Pérez Casas C, Scott C, Hill A, Clayden P, Flexner C. Impact of long-acting therapies on the global HIV epidemic. Aids (London, England). 35: S137-S143. PMID 34848580 DOI: 10.1097/QAD.0000000000003102 |
0.407 |
|
| 2021 |
Hurwitz SJ, Tao S, Gavegnano C, Jiang Y, Tressler R, Tsibris A, Del Rio C, Overton ET, Lederman MM, Kantor A, Moser C, Kohler JJ, Lennox J, Marconi VC, Flexner C, et al. Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agents Therapy from the ACTG A5336 Study. Journal of Clinical Pharmacology. PMID 34169526 DOI: 10.1002/jcph.1930 |
0.374 |
|
| 2021 |
Phillips AN, Bansi-Matharu L, Cambiano V, Ehrenkranz P, Serenata C, Venter F, Pett S, Flexner CW, Jahn A, Revill P, Garnett GP. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. The Lancet. Global Health. PMID 33770513 DOI: 10.1016/S2214-109X(21)00025-5 |
0.354 |
|
| 2021 |
Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, et al. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33693561 DOI: 10.1093/cid/ciab212 |
0.431 |
|
| 2020 |
Flexner C, Owen A, Siccardi M, Swindells S. LONG-ACTING DRUGS AND FORMULATIONS FOR THE TREATMENT AND PREVENTION OF HIV. International Journal of Antimicrobial Agents. 106220. PMID 33166693 DOI: 10.1016/j.ijantimicag.2020.106220 |
0.431 |
|
| 2020 |
Durand CM, Capoferri AA, Redd AD, Zahurak M, Rosenbloom DIS, Cash A, Avery RK, Bolaños-Meade J, Bollard CM, Bullen CK, Flexner C, Fuchs EJ, Gallant J, Gladstone DE, Gocke CD, et al. Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. The Lancet. Hiv. PMID 32649866 DOI: 10.1016/S2352-3018(20)30073-4 |
0.434 |
|
| 2020 |
Rajoli RKR, Demkovich ZR, Flexner C, Owen A, Siccardi M. Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling. Antimicrobial Agents and Chemotherapy. PMID 32423957 DOI: 10.1128/Aac.00155-20 |
0.355 |
|
| 2019 |
Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas DL, Flexner C. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. The Lancet. Hiv. PMID 31870675 DOI: 10.1016/S2352-3018(19)30342-X |
0.533 |
|
| 2019 |
Weld ED, Flexner C. Long-acting implants to treat and prevent HIV infection. Current Opinion in Hiv and Aids. PMID 31764198 DOI: 10.1097/Coh.0000000000000591 |
0.354 |
|
| 2019 |
K R Rajoli R, Flexner C, Chiong J, Owen A, Donnelly RF, Larrañeta E, Siccardi M. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. PMID 31525446 DOI: 10.1016/J.Ejpb.2019.09.011 |
0.401 |
|
| 2019 |
Nachman S, Townsend CL, Abrams EJ, Archary M, Capparelli E, Clayden P, Lockman S, Jean-Philippe P, Mayer K, Mirochnick M, McKenzie-White J, Struble K, Watts H, Flexner C. Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities. The Lancet. Hiv. PMID 31307946 DOI: 10.1016/S2352-3018(19)30147-X |
0.311 |
|
| 2019 |
Hobson JJ, Al-Khouja A, Curley P, Meyers D, Flexner C, Siccardi M, Owen A, Meyers CF, Rannard SP. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. Nature Communications. 10: 1413. PMID 30926773 DOI: 10.1038/S41467-019-09354-Z |
0.34 |
|
| 2018 |
Kent SJ, Flexner C. Ageing in patients with chronic HIV infection: impact of hypercoagulation. Aids Research and Therapy. 15: 22. PMID 30474565 DOI: 10.1186/s12981-018-0211-1 |
0.399 |
|
| 2018 |
Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH, Chakraborty R, Swindells S, Flexner C, Agwu AL. Interest of Youth Living with HIV in Long-Acting Antiretrovirals. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 30418298 DOI: 10.1097/QAI.0000000000001896 |
0.392 |
|
| 2018 |
Flexner C. Modern HIV Therapy: Progress and Prospects. Clinical Pharmacology and Therapeutics. PMID 30411787 DOI: 10.1002/cpt.1284 |
0.377 |
|
| 2018 |
Flexner C, Thomas DL, Swindells S. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. Current Opinion in Hiv and Aids. PMID 30394948 DOI: 10.1097/Coh.0000000000000510 |
0.35 |
|
| 2018 |
Gulick RM, Flexner C. Long-Acting HIV Drugs for Treatment and Prevention. Annual Review of Medicine. PMID 30355266 DOI: 10.1146/annurev-med-041217-013717 |
0.401 |
|
| 2018 |
Monroe M, Flexner C, Cui H. Harnessing nanostructured systems for improved treatment and prevention of HIV disease. Bioengineering & Translational Medicine. 3: 102-123. PMID 30065966 DOI: 10.1002/btm2.10096 |
0.376 |
|
| 2017 |
Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. Aids (London, England). 31: S173-S184. PMID 28471948 DOI: 10.1097/QAD.0000000000001401 |
0.364 |
|
| 2017 |
Maartens G, Boffito M, Flexner C. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. Current Opinion in Hiv and Aids. PMID 28403028 DOI: 10.1097/COH.0000000000000376 |
0.302 |
|
| 2017 |
Jacobson JM, Flexner C. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day. Current Opinion in Hiv and Aids. PMID 28368868 DOI: 10.1097/COH.0000000000000374 |
0.417 |
|
| 2016 |
Jacobson J, Bosinger S, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson C, Flexner CW, Clagett B, Plants J, Read S, Purdue L, Myers L, Boone L, Tebas P, Kumar P, et al. The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. Aids Research and Human Retroviruses. PMID 26935044 DOI: 10.1089/Aid.2015.0336 |
0.473 |
|
| 2016 |
Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, Peloquin CA, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson MO. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. The Journal of Antimicrobial Chemotherapy. PMID 26832753 DOI: 10.1093/Jac/Dkv470 |
0.504 |
|
| 2015 |
Nelson AG, Zhang X, Ganapathi U, Szekely Z, Flexner CW, Owen A, Sinko PJ. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26315816 DOI: 10.1016/J.Jconrel.2015.08.042 |
0.481 |
|
| 2015 |
Rajoli RK, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, Siccardi M. Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. Clinical Pharmacokinetics. 54: 639-50. PMID 25523214 DOI: 10.1007/S40262-014-0227-1 |
0.495 |
|
| 2015 |
Cash A, Capoferri A, Xu D, Mchugh H, Laeyendecker O, Sakoian S, Tony L, Bullen C, Pohlmeyer C, Pham P, Lai J, Gallant J, Siliciano R, Flexner C, Pratz K, et al. Safety of Optimized Antiretroviral Therapy During Allogeneic Matched and Haploidentical Bone Marrow Transplant in HIV+ Individuals Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv131.83 |
0.402 |
|
| 2014 |
Vitoria M, Ford N, Doherty M, Flexner C. Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings. Antiviral Therapy. 19: 31-7. PMID 25310534 DOI: 10.3851/IMP2898 |
0.334 |
|
| 2014 |
Zheng L, Taiwo B, Gandhi RT, Hunt PW, Collier AC, Flexner C, Bosch RJ. Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 153-60. PMID 25072610 DOI: 10.1097/QAI.0000000000000286 |
0.348 |
|
| 2013 |
Flexner C, Saag M. The antiretroviral drug pipeline: prospects and implications for future treatment research. Current Opinion in Hiv and Aids. 8: 572-8. PMID 24100879 DOI: 10.1097/Coh.0000000000000011 |
0.459 |
|
| 2013 |
Flexner C, Plumley B, Brown Ripin DH. Treatment optimization: an outline for future success. Current Opinion in Hiv and Aids. 8: 523-7. PMID 24100878 DOI: 10.1097/Coh.0000000000000003 |
0.35 |
|
| 2013 |
Ford N, Flexner C, Vella S, Ripin D, Vitoria M. Optimization and simplification of antiretroviral therapy for adults and children. Current Opinion in Hiv and Aids. 8: 591-9. PMID 24100871 DOI: 10.1097/Coh.0000000000000010 |
0.396 |
|
| 2013 |
Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM. Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 57: 1607-17. PMID 24046302 DOI: 10.1093/Cid/Cit595 |
0.468 |
|
| 2013 |
Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. The Journal of Infectious Diseases. 208: 884-91. PMID 23801609 DOI: 10.1093/Infdis/Jit272 |
0.427 |
|
| 2013 |
Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, Flexner C, Swindells S. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (London, England). 8: 1807-13. PMID 23611617 DOI: 10.2217/Nnm.12.214 |
0.441 |
|
| 2013 |
Durand CM, Flexner C. HIV cure: Knocking on the door Clinical Pharmacology and Therapeutics. 93: 382-384. PMID 23598454 DOI: 10.1038/clpt.2013.22 |
0.438 |
|
| 2013 |
Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. Journal of Acquired Immune Deficiency Syndromes (1999). 62: 21-7. PMID 23075918 DOI: 10.1097/Qai.0B013E318276Cda9 |
0.515 |
|
| 2012 |
Lee LS, Pham P, Flexner C. Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz. Annals of the Academy of Medicine, Singapore. 41: 559-62. PMID 23303112 |
0.329 |
|
| 2012 |
Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint NA, Tannenbaum SR, Hendrix CW, Fuchs EJ. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. Journal of Acquired Immune Deficiency Syndromes (1999). 61: 593-9. PMID 23187888 DOI: 10.1097/Qai.0B013E3182717C98 |
0.348 |
|
| 2012 |
Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. The Lancet. Infectious Diseases. 12: 550-60. PMID 22742638 DOI: 10.1016/S1473-3099(12)70134-2 |
0.385 |
|
| 2012 |
Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. Journal of Acquired Immune Deficiency Syndromes (1999). 59: 455-62. PMID 22126739 DOI: 10.1097/Qai.0B013E3182410503 |
0.404 |
|
| 2011 |
Wang L, Soon GH, Seng KY, Li J, Lee E, Yong EL, Goh BC, Flexner C, Lee L. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrobial Agents and Chemotherapy. 55: 4090-5. PMID 21746959 DOI: 10.1128/Aac.00593-11 |
0.322 |
|
| 2011 |
Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. The Lancet. Oncology. 12: 905-12. PMID 21570912 DOI: 10.1016/S1470-2045(11)70056-0 |
0.463 |
|
| 2011 |
Wang LZ, Lee LS, Thuya WL, Soon GH, Kong LR, Nye PL, Lee EJ, Flexner C, Goh BC. Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method. Journal of Mass Spectrometry : Jms. 46: 202-8. PMID 21259392 DOI: 10.1002/Jms.1874 |
0.325 |
|
| 2011 |
Pham PA, Flexner C. Emerging antiretroviral drug interactions. The Journal of Antimicrobial Chemotherapy. 66: 235-9. PMID 21131695 DOI: 10.1093/Jac/Dkq448 |
0.375 |
|
| 2010 |
Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. Journal of Acquired Immune Deficiency Syndromes (1999). 54: 470-6. PMID 20672447 DOI: 10.1097/Qai.0B013E3181E2Cba0 |
0.486 |
|
| 2010 |
Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, Stocker V, Lederman MM, Flexner C. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. Aids Research and Human Retroviruses. 26: 635-43. PMID 20560793 DOI: 10.1089/Aid.2009.0154 |
0.466 |
|
| 2010 |
Soon GH, Shen P, Yong EL, Pham P, Flexner C, Lee L. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers. Antimicrobial Agents and Chemotherapy. 54: 2775-80. PMID 20385850 DOI: 10.1128/Aac.01564-09 |
0.371 |
|
| 2010 |
Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 50: 1041-52. PMID 20192725 DOI: 10.1086/651118 |
0.454 |
|
| 2010 |
Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C. Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). Journal of Acquired Immune Deficiency Syndromes (1999). 53: 598-605. PMID 20071999 DOI: 10.1097/QAI.0b013e3181c9caac |
0.429 |
|
| 2009 |
Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, Piliero PJ, Barditch-Crovo P, Fuchs E, Flexner C, Cameron DW. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrobial Agents and Chemotherapy. 53: 4385-92. PMID 19667285 DOI: 10.1128/Aac.00449-09 |
0.306 |
|
| 2009 |
Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, Flanigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Archives of Internal Medicine. 169: 1224-32. PMID 19597072 DOI: 10.1001/Archinternmed.2009.172 |
0.395 |
|
| 2009 |
Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. Plos One. 4: e5683. PMID 19479085 DOI: 10.1371/Journal.Pone.0005683 |
0.311 |
|
| 2008 |
Andrade AS, Hendrix C, Parsons TL, Caballero B, Yuan CS, Flexner CW, Dobs AS, Brown TT. Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. Bmc Complementary and Alternative Medicine. 8: 50. PMID 18713456 DOI: 10.1186/1472-6882-8-50 |
0.45 |
|
| 2008 |
Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. Journal of Virology. 82: 8210-4. PMID 18495779 DOI: 10.1128/JVI.00444-08 |
0.305 |
|
| 2008 |
Lee LS, Wise SD, Chan C, Parsons TL, Flexner C, Lietman PS. Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. Journal of Clinical Pharmacology. 48: 599-609. PMID 18319359 DOI: 10.1177/0091270008314252 |
0.362 |
|
| 2008 |
Cao YJ, Flexner CW, Dunaway S, Park JG, Klingman K, Wiggins I, Conley J, Radebaugh C, Kashuba AD, MacFarland R, Becker S, Hendrix CW. Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrobial Agents and Chemotherapy. 52: 1630-4. PMID 18285477 DOI: 10.1128/AAC.01460-07 |
0.505 |
|
| 2008 |
Willard S, Flexner C. Introduction: The changing face of HIV Journal of the International Association of Physicians in Aids Care. 7. DOI: 10.1177/1545109708315400 |
0.381 |
|
| 2007 |
Bakshi RP, Hamzeh F, Frank I, Eron JJ, Bosch RJ, Rosenkranz SL, Cramer YS, Ussery M, Flexner C. Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. Aids Research and Human Retroviruses. 23: 1360-5. PMID 18184078 DOI: 10.1089/Aid.2007.0078 |
0.485 |
|
| 2007 |
Flexner C. HIV drug development: the next 25 years. Nature Reviews. Drug Discovery. 6: 959-66. PMID 17932493 DOI: 10.1038/Nrd2336 |
0.454 |
|
| 2007 |
Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. Hiv Clinical Trials. 8: 193-204. PMID 17720659 DOI: 10.1310/Hct0804-193 |
0.422 |
|
| 2007 |
Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. The Journal of Infectious Diseases. 196: 304-12. PMID 17570119 DOI: 10.1086/518797 |
0.534 |
|
| 2007 |
Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao YJ, Wiggins IP, Conley J, MacFarland RT, Park JG, Lalama C, Snyder S, Kallungal B, Klingman KL, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrobial Agents and Chemotherapy. 51: 2351-8. PMID 17452489 DOI: 10.1128/Aac.00013-07 |
0.553 |
|
| 2007 |
Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999). 45: 201-5. PMID 17414932 DOI: 10.1097/Qai.0B013E318050D632 |
0.45 |
|
| 2007 |
Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 44: 591-5. PMID 17243065 DOI: 10.1086/511035 |
0.389 |
|
| 2006 |
De Gruttola V, Flexner C, Schapiro J, Hughes M, Van Der Laan M, Kuritzkes DR. Drug development strategies for salvage therapy: conflicts and solutions. Aids Research and Human Retroviruses. 22: 1106-9. PMID 17147496 DOI: 10.1089/Aid.2006.22.1106 |
0.369 |
|
| 2006 |
Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J, Gallant JE, Carson KA, Siliciano RF, Flexner C. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 42: 1189-96. PMID 16575741 DOI: 10.1086/501458 |
0.413 |
|
| 2005 |
Nettles RE, Keiffer TL, Cofrancesco J, Gallant JE, Quinn T, Jackson B, Flexner C, Carson KA, Wu AW, Siliciano RF. Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAART. Hiv Clinical Trials. 6: 262-71. PMID 16425464 DOI: 10.1310/5X2L-Mvy7-Yqtb-Ebaj |
0.349 |
|
| 2005 |
Flexner C. Update from the 6th International Workshop on the Clinical Pharmacology of HIV Therapy: new drugs, new formulations and drug interactions. The Hopkins Hiv Report : a Bimonthly Newsletter For Healthcare Providers / Johns Hopkins University Aids Service. 17: 1-3, 10-1. PMID 16419306 |
0.335 |
|
| 2005 |
Back DJ, Burger DM, Flexner CW, Gerber JG. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. Journal of Acquired Immune Deficiency Syndromes (1999). 39: S1-23, quiz S24-25. PMID 15990598 DOI: 10.1097/01.qai.0000168882.67942.3f |
0.316 |
|
| 2005 |
Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antiviral Therapy. 10: 375-92. PMID 15918329 |
0.301 |
|
| 2005 |
Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. Jama. 293: 817-29. PMID 15713771 DOI: 10.1001/Jama.293.7.817 |
0.429 |
|
| 2004 |
Frank I, Bosch RJ, Fiscus S, Valentine F, Flexner C, Segal Y, Ruan P, Gulick R, Wood K, Estep S, Fox L, Nevin T, Stevens M, Eron JJ. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. Aids Research and Human Retroviruses. 20: 916-26. PMID 15597521 DOI: 10.1089/Aid.2004.20.916 |
0.427 |
|
| 2004 |
Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, Bridger GJ, Badel K, MacFarland RT, Henson GW, Calandra G, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes (1999). 37: 1253-62. PMID 15385732 DOI: 10.1097/01.Qai.0000137371.80695.Ef |
0.452 |
|
| 2004 |
Tapper ML, Flexner C, Eron JJ, Molina JM. Simplifying antiretroviral therapy. The Aids Reader. 14: 355-60, 367-71. PMID 15282865 |
0.345 |
|
| 2004 |
Rufo PA, Lin PW, Andrade A, Jiang L, Rameh L, Flexner C, Alper SL, Lencer WI. Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. American Journal of Physiology. Cell Physiology. 286: C998-C1008. PMID 15075198 DOI: 10.1152/Ajpcell.00357.2003 |
0.409 |
|
| 2003 |
Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clinical Pharmacology and Therapeutics. 73: 406-16. PMID 12732841 DOI: 10.1016/S0009-9236(03)00006-7 |
0.31 |
|
| 2003 |
Flexner CW. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. Topics in Hiv Medicine : a Publication of the International Aids Society, Usa. 11: 40-4. PMID 12717040 |
0.362 |
|
| 2003 |
Rufo P, Lin PW, Andrade A, Flexner C, Jiang L, Alper SL, Lencer WI. HIV-1 protease inhibitors potentiate muscarinic stimulation of Clȡ secretion in association with increased and prolonged Ca2+ entry in T84 cells Gastroenterology. 124: A144. DOI: 10.1016/S0016-5085(03)80714-X |
0.44 |
|
| 2002 |
Lucas GM, Flexner CW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? Aids Patient Care and Stds. 16: 527-35. PMID 12513901 DOI: 10.1089/108729102761041083 |
0.337 |
|
| 2002 |
Lu JF, Blaschke TF, Flexner C, Rosenkranz SL, Sheiner LB. Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 1455-61. PMID 12433819 DOI: 10.1124/Dmd.30.12.1455 |
0.301 |
|
| 2002 |
Acosta EP, Fletcher CV, Flexner C, Haas D, Hall S, Hamzeh F, Haubrich R, Kashuba A, Katzenstein D, Lawrence J, Lertora J, Gerber JG, Para M, Rosenkranz S, Sheiner L, et al. Position paper on therapeutic drug monitoring of antiretroviral agents Aids Research and Human Retroviruses. 18: 825-834. PMID 12201904 DOI: 10.1089/08892220260190290 |
0.364 |
|
| 2002 |
Kresina TF, Flexner CW, Sinclair J, Correia MA, Stapleton JT, Adeniyi-Jones S, Cargill V, Cheever LW. Alcohol use and HIV pharmacotherapy. Aids Research and Human Retroviruses. 18: 757-70. PMID 12167267 DOI: 10.1089/08892220260139495 |
0.319 |
|
| 2002 |
Speck RR, Yu XF, Hildreth J, Flexner C. Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. The Journal of Infectious Diseases. 186: 332-40. PMID 12134229 DOI: 10.1086/341464 |
0.713 |
|
| 2002 |
Flexner CW, Piscitelli SC. Concentration-targeted therapy and the future of HIV management. Aids (London, England). 16: S1-3. PMID 12035819 |
0.352 |
|
| 2001 |
Flexner C. The future of HIV treatment: I left my HAART in the 20th century The Hopkins Hiv Report : a Bimonthly Newsletter For Healthcare Providers / Johns Hopkins University Aids Service. 13: 3-5. PMID 11682854 |
0.374 |
|
| 2001 |
Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A, Gal J. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. Journal of Acquired Immune Deficiency Syndromes (1999). 27: 153-60. PMID 11404537 DOI: 10.1097/00126334-200106010-00010 |
0.368 |
|
| 2001 |
Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy Journal of Clinical Oncology. 19: 2171-2178. PMID 11304769 DOI: 10.1200/Jco.2001.19.8.2171 |
0.379 |
|
| 2001 |
Flexner CW, Cargill VA, Sinclair J, Kresina TF, Cheever L. Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy Aids Patient Care and Stds. 15: 57-58. PMID 11224929 DOI: 10.1089/108729101300003636 |
0.319 |
|
| 2001 |
Lederman M, Mosier D, Arts E, Letvin N, Flexner C, Blauvelt A, Cairns S, Bridges S, Sarver N, Offord R. Rationale for testing chemokine inhibitors (Virustats) for prevention of HIV-1 transmission. Aids. 15: S57-S58. DOI: 10.1097/00002030-200102001-00081 |
0.498 |
|
| 2000 |
Andrade A, Flexner C. HIV-related drug metabolism and cytochrome P450 enzymes Aids Clinical Care. 12: 91-95. PMID 2002150695 |
0.366 |
|
| 2000 |
Flexner C, Bartlett JG. Complications of HIV therapy The Hopkins Hiv Report : a Bimonthly Newsletter For Healthcare Providers / Johns Hopkins University Aids Service. 12. PMID 12184226 |
0.397 |
|
| 2000 |
Raines CP, Flexner C, Sun E, Heath-Chiozzi M, Lewis RH, Fields C, Deetz C, Apuzzo L, Eshleman SH, Jackson JB, Gallant JE. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. Journal of Acquired Immune Deficiency Syndromes (1999). 25: 322-8. PMID 11114832 DOI: 10.1097/00042560-200012010-00005 |
0.438 |
|
| 2000 |
Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. The Journal of Biological Chemistry. 275: 41325-32. PMID 11018036 DOI: 10.1074/Jbc.M006474200 |
0.467 |
|
| 2000 |
Flexner C. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits Annual Review of Pharmacology and Toxicology. 40: 649-674. PMID 10836150 |
0.46 |
|
| 2000 |
Speck RR, Flexner C, Tian CJ, Yu XF. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrobial Agents and Chemotherapy. 44: 1397-403. PMID 10770790 DOI: 10.1128/Aac.44.5.1397-1403.2000 |
0.723 |
|
| 2000 |
Lin PW, Rufo PA, Flexner C, Lencer WI. The HIV-1 protease inhibitor nelfinvir enhances CA++-dependent Cl- secretion in intestinal T84 cell monolayers Gastroenterology. 118: A607. DOI: 10.1016/S0016-5085(00)84566-7 |
0.439 |
|
| 1999 |
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine. 5: 512-7. PMID 10229227 DOI: 10.1038/8394 |
0.396 |
|
| 1999 |
Ratner L, Redden D, Hamzeh F, Levine A, Harrington W, Scadden D, Kaplan L, Ambinder R, Grochow L, Flexner C, Tan B, Straus D. CHEMOTHERAPY FOR HIV-ASSOCIATED NON-HODGKIN LYMPHOMA (HIV-NHL) IN COMBINATION WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS NOT ASSOCIATED WITH EXCESSIVE TOXICITY. Jaids: Journal of Acquired Immune Deficiency Syndromes. 21: A32. DOI: 10.1097/00126334-199905010-00112 |
0.505 |
|
| 1998 |
Flexner C. Fat city: understanding HIV lipodystrophy The Hopkins Hiv Report : a Bimonthly Newsletter For Healthcare Providers / Johns Hopkins University Aids Service. 10: 14-15. PMID 11365774 |
0.406 |
|
| 1998 |
Di Perri G, Del Bravo P, Concia E, Palleja S, Flexner CW. HIV-protease inhibitors [4] (multiple letters) New England Journal of Medicine. 339: 773-774. PMID 9742031 DOI: 10.1056/NEJM199809103391115 |
0.438 |
|
| 1998 |
Maenza J, Flexner C. Combination antiretroviral therapy for HIV infection American Family Physician. 57: 2789-2798. PMID 9636341 |
0.377 |
|
| 1998 |
Flexner C. HIV-protease inhibitors New England Journal of Medicine. 338: 1281-1292. PMID 9562584 DOI: 10.1056/Nejm199804303381808 |
0.559 |
|
| 1998 |
Yu XF, Dawson L, Tian CJ, Flexner C, Dettenhofer M. Mutations of the human immunodeficiency virus type 1 p6(Gag) domain result in reduced retention of pol proteins during virus assembly Journal of Virology. 72: 3412-3417. PMID 9525672 DOI: 10.1128/Jvi.72.4.3412-3417.1998 |
0.448 |
|
| 1997 |
Fischl MA, Richman DD, Flexner C, Para MF, Haubrich R, Karim A, Yeramian P, Holden-Wiltse J, Meehan PM. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151 Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 15: 28-34. PMID 9215651 DOI: 10.1097/00042560-199705010-00005 |
0.413 |
|
| 1997 |
Sharma UK, Song HF, Willingham FF, Hannig J, Flexner C, Farzadegan H, Nicolau C, Schwartz DH. Diagnosis of human immunodeficiency virus infection using citrated whole blood. Clinical and Diagnostic Laboratory Immunology. 4: 261-3. PMID 9144360 |
0.369 |
|
| 1997 |
Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 23: 685-93. PMID 8909827 DOI: 10.1093/Clinids/23.4.685 |
0.382 |
|
| 1997 |
Hammond JMJ, Hannig J, Schwartz D, Flexner C. Survival kinetics of autologous erythrocytes (RBCs) modified by electroinsertion of recombinant CD4 Clinical Pharmacology and Therapeutics. 61: 193. |
0.359 |
|
| 1996 |
Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, Vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy American Journal of Medicine. 101: 68-76. PMID 8686718 DOI: 10.1016/S0002-9343(96)00070-8 |
0.319 |
|
| 1996 |
Tosi PF, Schwartz D, Sharma U, Mouneimne Y, Hannig J, Li G, McKinley G, Grieco M, Flexner CW, Lazarte J, Norse D, Nicolau C, Volsky DJ. Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1. Blood. 87: 4839-44. PMID 8639857 |
0.369 |
|
| 1995 |
Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, Flexner C, Dando S, Mattiacci MR, Ahlers CM, Zhang L, Novick WJ, Kasdan P, Fahey JL, Pardee AB, Crumpacker CS. High-dose pentoxifylline in patients with AIDS: Inhibition of tumor necrosis factor production Journal of Infectious Diseases. 171: 1628-1632. PMID 7769305 DOI: 10.1093/Infdis/171.6.1628 |
0.334 |
|
| 1995 |
Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, Lietman P, Hamzeh FM, Spector SA, Richman DD, Hammer S, Cooley T, Gulick R, Sullivan M, Spina C, et al. A randomized trial of the activity and safety of ro 24-7429 (tat antagonist) versus nucleoside for human immunodeficiency virus infection Journal of Infectious Diseases. 172: 1246-1252. PMID 7594660 DOI: 10.1093/Infdis/172.5.1246 |
0.488 |
|
| 1995 |
Chavan SJ, Bornmann WG, Flexner C, Prochaska HJ. Inactivation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase by Oltipraz: Evidence for the Formation of a Stable Adduct Archives of Biochemistry and Biophysics. 324: 143-152. PMID 7503549 DOI: 10.1006/abbi.1995.9916 |
0.371 |
|
| 1994 |
Hendrix CW, Flexner C, Szebeni J, Kuwahara S, Pennypacker S, Weinstein JN, Lietman PS. Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects Antimicrobial Agents and Chemotherapy. 38: 1036-1040. PMID 8067734 DOI: 10.1128/Aac.38.5.1036 |
0.402 |
|
| 1994 |
Flexner C, Van Der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, Barditch-Crovo PA, Petty BG, Baron PA, Armstrong D, Bricmont P, Kuye O, Yacobi A, Desjardins R, Polsky B. Relationship between plasma concentrations of 3‘-deoxy-3’-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials Journal of Infectious Diseases. 170: 1394-1403. PMID 7995977 DOI: 10.1093/infdis/170.6.1394 |
0.388 |
|
| 1992 |
Stein D, Corey L, Volberding P, Jermano J, Dixon D, Feldstein M, Flexner C, Freeman D, Grieco M, Havlir D, Leedom J, Mitsuyasu R, Para M, Sacks H, Seidlin M. Preliminary safety and activity evaluation of new agents for the treatment of HIV-1 infection: Recommended guidelines for trial design Controlled Clinical Trials. 13: 388. DOI: 10.1016/0197-2456(92)90069-C |
0.437 |
|
| 1991 |
Moore RD, Kessler H, Richman DD, Flexner C, Chaisson RE. Non-Hodgkin’s Lymphoma in Patients With Advanced HIV Infection Treated With Zidovudine Jama: the Journal of the American Medical Association. 265: 2208-2211. PMID 2013953 DOI: 10.1001/Jama.1991.03460170062034 |
0.419 |
|
| 1991 |
Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, Bell KM, Lorentsen KJ, Hendrix CW, Petty BG, Lietman PS. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection Antimicrobial Agents and Chemotherapy. 35: 2544-2550. PMID 1810188 DOI: 10.1128/Aac.35.12.2544 |
0.565 |
|
| 1991 |
Flexner C, Barditch-Crovo P, Kornhauser D, Nerhood L, Hendrix C, Lorentsen K, Farzadegan H, Petty B, Lietman P. Intravenous dextran sulfate (DS) increases circulating HIV antigen levels in patients with ARC or AIDS Antiviral Research. 15: 125. DOI: 10.1016/0166-3542(91)90240-R |
0.487 |
|
| 1990 |
Hosmalin A, Clerici M, Houghten R, Pendleton CD, Flexner C, Lucey DR, Moss B, Germain RN, Shearer GM, Berzofsky JA. An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes Proceedings of the National Academy of Sciences of the United States of America. 87: 2344-2348. PMID 1690429 DOI: 10.1073/Pnas.87.6.2344 |
0.416 |
|
| 1989 |
Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B, Schooley RT. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1 Proceedings of the National Academy of Sciences of the United States of America. 86: 9514-9518. PMID 2480604 DOI: 10.1073/Pnas.86.23.9514 |
0.344 |
|
| 1989 |
Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, Klecker RW, Flexner C, Eckel RH, Lietman PS. Dextran sulfate is poorly absorbed after oral administration Annals of Internal Medicine. 111: 561-566. PMID 2476054 DOI: 10.7326/0003-4819-111-7-561 |
0.334 |
|
| 1988 |
Flexner C, Broyles SS, Earl P, Chakrabarti S, Moss B. Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses Virology. 166: 339-349. PMID 2459842 DOI: 10.1016/0042-6822(88)90504-1 |
0.442 |
|
| 1988 |
Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley RT, Moss B. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals Science. 240: 64-66. PMID 2451288 DOI: 10.1126/Science.2451288 |
0.437 |
|
| Show low-probability matches. |